Related Experiment Videos
Clodronate prevents bone loss in aged ovariectomized rats
K Kippo1, R Hannuniemi, L Laurén
1Leiras Oy, Biomedical Research Center, P.O. Box 415, 20101 Turku, Finland.
Calcified Tissue International
|August 1, 1997
Summary
Clodronate effectively prevents bone loss and reduces bone resorption in ovariectomized rats. This bisphosphonate treatment maintained bone mass and strength without adverse effects.
Area of Science:
- Bone biology and pharmacology
- Osteoporosis research
- Animal models of bone disease
Background:
- Ovariectomy-induced osteopenia is a common model for postmenopausal osteoporosis.
- Bisphosphonates are a class of drugs used to treat bone loss.
Purpose of the Study:
- To evaluate clodronate's efficacy in preventing ovariectomy-induced osteopenia in aged rats.
- To assess clodronate's effects on bone resorption and formation markers.
Main Methods:
- Aged female Sprague-Dawley rats underwent ovariectomy (OVX) or sham operation.
- OVX rats received weekly subcutaneous injections of vehicle or clodronate (3, 7, or 25 mg/kg) for 3 months.
- Bone mineral density, bone resorption (urinary deoxypyridinoline), and bone formation (serum osteocalcin) were assessed.
Main Results:
- Clodronate inhibited trabecular bone loss in the femur and lumbar vertebrae at all doses.
- Bone resorption markers decreased, while bone formation markers were preserved at lower doses.
- The highest clodronate dose reduced OVX-induced periosteal bone formation and improved cortical bone parameters.
- No adverse effects on bone quality or mechanical strength were observed.
Conclusions:
- Clodronate is effective in preventing OVX-induced osteopenia and bone loss in aged rats.
- The drug demonstrated a dose-dependent effect on bone resorption and formation.
- Clodronate treatment did not compromise the mechanical integrity of the bone.